Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
This trial was conducted in the United States of America (USA). The aim of this trial was to
investigate safety and pharmacokinetics of escalating single doses of catridecacog
(recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.